CytomX Therapeutics Inc 6C1.BE
€3.49 €0.09 (2.41%) 1D
Last Updated: Dec 17, 12:00 AM·BE
Pricing for DE stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is CytomX Therapeutics Inc Stock Halal?
Shariah Compliance Analysis of 6C1.BE Stock
Germany Health Care Small Cap No. As of September 2026, CytomX Therapeutics Inc (6C1.BE) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. CytomX Therapeutics Inc does not pass Musaffa's business and financial screening criteria.
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company is headquartered in South San Francisco, California and currently employs 119 full-time employees. The company went IPO on 2015-10-08. The firm is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The firm is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
6C1.BE Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, CytomX Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
CytomX Therapeutics Inc (6C1.BE) Chart
Financial Metrics & Statements of CytomX Therapeutics Inc (6C1.BE)
FAQ's for CytomX Therapeutics Inc (6C1.BE)
- As of September 2026, CytomX Therapeutics Inc 6C1.BE is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes CytomX Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in CytomX Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of CytomX Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of CytomX Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of CytomX Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for CytomX Therapeutics Inc (6C1.BE)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
